Clinical trials: Neoplasms, Oral
Metastatic Breast Cancer
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
This multicenter, Phase Ib study is an open label, dose escalation, three-arm study evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941 administered in combination with either intravenous…
- Trial name
- NCT00928330
- Testing
- GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Genentech, Inc.
Sarcoma, Breast Cancer
Augmented Reality (AR): The Future of "Patient Information Leaflets
This project aims to assess a new type of Augmented Reality Patient Information leaflet, in order to demonstrate that it is a beneficial information resource to patients when facing the diagnosis of sarcoma, breast cancer or to…
- Conditions
- Sarcoma, Breast Cancer, Cleft Lip and Palate, Surgical Flap
- Trial name
- NCT04619030
- Testing
- Augmented Reality, Traditional leaflet
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- NHS Greater Glasgow and Clyde
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486, known as oral azacitidine, in patients with AML or MDS after allogeneic hematopoetic stem cell transplant (HSCT).
- Trial name
- NCT01835587
- Testing
- CC-486
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Stomach
Early Oral Feeding After Total Gastrectomy for Cancer
The aim of this study is to evaluate the possibility of shortening postoperative hospital stay after gastrectomy by early oral feeding as a component of an enhanced recovery protocol (ERAS).
- Trial name
- NCT01962519
- Testing
- Early oral feeding
- Where
- Poland
- Volunteers
- 112 people
- Sponsor
- Jagiellonian University
Oral Squamous, Cell Carcinoma
Radio/Pathological Evaluation of Tongue Cancer Infiltration
The aim of the study is to assess the good correlation and prediction of the DOI for the post-operative pathological results and prognosis.
- Trial name
- RaP E ToC (NCT04821128)
- Testing
- Radiologic and pathological review.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer.
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Trial name
- NCT06819228
- Testing
- Panitumumab IRDye 800
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumors
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized.
- Trial name
- NCT00778128
- Testing
- CP-4126, Gemcitabine
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 26 people
- Sponsor
- Clavis Pharma
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Multicentre Real-life Data Collection Study With CareMin650™ in the Prevention and Treatment of Oral Mucositis and Radio- and/or Chemo-induced Dermatitis
Most patients with cancer or haematological malignancies who receive chemotherapy - broadly defined to include targeted therapies and immunotherapy - and/or external beam radiotherapy may experience serious and disabling adverse…
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Oral Mucositis (Ulcerative) Due to Radiation, Dermatitis
- Trial name
- NéoPBM (NCT07054528)
- Where
- France
- Volunteers
- 33,000 people
- Sponsor
- Centre Hospitalier de Valenciennes
Advanced Solid Tumor
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
In this study, MEK162 will be administered to Japanese patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01469130
- Testing
- MEK162
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
the Severity and Duration of Intraoperative Hypotension
Applying HPI in Oral Cancer Surgery
Investigating HPI effect in oral cancer surgery
- Trial name
- NCT07405892
- Testing
- HPI, HPI silence
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Carcinoid Tumors, Neuroendocrine Tumors
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
This is a research study looking at the effect of 5-Hydroxy Tryptophan (5-HTP) on urine excretion of 5-Hydroxyindolacetic acid (5-HIAA).
- Trial name
- NCT00227136
- Testing
- 5-Hydroxy-Tryptamine
- Where
- Canada
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Western Ontario, Canada
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Pancreas Neoplasms
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas.
- Trial name
- DOVIPA (NCT06757244)
- Testing
- Dostarlimab, Vitamin D3 (Cholecalciferol), mFOLFIRINOX Treatment Regimen
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- Hopital Foch
Dysplasia, Lip and Oral Cavity Carcinoma
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders.
- Conditions
- Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder, Premalignant Lesion
- Trial name
- NCT02790853
- Testing
- Biopsy, Fluorescence Imaging, High-Resolution Microendoscopy
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer.
- Trial name
- NCT06206837
- Testing
- vepdegestrant, PF-07220060
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia
Oral Azacitidine Maintenance Post-CPX 351
Approximately 10% of patient develop AML after chemotherapy or radiation for unrelated disease (t-AML) and 20% have AML with an antecedent hematologic disorder (AML-MRC).
- Trial name
- ORAZ-351 (NCT06349239)
- Testing
- No intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Oral Mucositis, Osteoradionecrosis
Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention
Introduction: There are several manifestations in the oral mucosa resulting from antineoplastic treatments by chemo (QT) or radiotherapy (RT).
- Conditions
- Oral Mucositis, Osteoradionecrosis, Osteonecroses, Bisphosphonate, Osteonecrosis Due to Drugs, Jaw
- Trial name
- NCT04717765
- Testing
- Preventive, LLL Phototherapy and topical Vit E, Curative, LLL Phototherapy and topical Vit E, Preventive, LLL Phototherapy and LPRF
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- University of Santiago de Compostela
Head and Neck Cancer, Oral Cancer
Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings - Optimization Phase
This study aims to develop and evaluate a low-cost, portable, flexible nasopharyngeal scope (FNS) used to assess head and neck cancers (HNC) in low resource settings.
- Trial name
- NCT04905134
- Testing
- Nasopharyngoscope
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Duke University
Oral Cancer
The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor
Cervical nodal metastasis is the most certain prognostic factor in oral cancer. Appropriate management of the neck is therefore of paramount importance in the treatment of oral cancer.
- Trial name
- NCT03017053
- Testing
- Radiotherapy, Elective neck dissection
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.